Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 4 | 1 | — | — | 5 |
Fatty liver | D005234 | EFO_0003934 | — | — | 4 | 1 | — | — | 5 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 3 | 1 | — | — | 4 |
Covid-19 | D000086382 | — | — | — | 2 | 1 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 5 | — | — | 1 | 7 |
Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | 2 | — | — | — | 3 |
Arteritis | D001167 | EFO_0009011 | I77.6 | — | 2 | — | — | — | 2 |
Inflammation | D007249 | MP_0001845 | — | — | 2 | — | — | — | 2 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 1 | — | — | — | 2 |
Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
Sclerosing cholangitis | D015209 | EFO_0004268 | K83.01 | — | 1 | — | — | — | 1 |
Cholangitis | D002761 | HP_0030151 | K83.0 | — | 1 | — | — | — | 1 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Hepatic insufficiency | D048550 | — | — | 2 | — | — | — | — | 2 |
Liver failure | D017093 | HP_0001399 | K72.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 1 | 1 |
Drug common name | Cenicriviroc |
INN | cenicriviroc |
Description | Cenicriviroc is a member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). It has a role as a chemokine receptor 5 antagonist, an anti-HIV agent, a chemokine receptor 2 antagonist, an antirheumatic drug and an anti-inflammatory agent. It is a diether, a member of imidazoles, a sulfoxide, an aromatic ether, a secondary carboxamide and a benzazocine. |
Classification | Small molecule |
Drug class | antivirals; antivirals, chemokine receptor (CCR) antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1 |
PDB | — |
CAS-ID | 497223-25-3 |
RxCUI | — |
ChEMBL ID | CHEMBL2110727 |
ChEBI ID | — |
PubChem CID | 11285792 |
DrugBank | DB11758 |
UNII ID | 15C116UA4Y (ChemIDplus, GSRS) |